Clinical Takeaway
Children born to mothers who used cannabis during pregnancy showed a modestly elevated risk of autism spectrum disorder and a smaller increase in risk of ADHD, based on a pooled analysis of 13 observational studies. Cannabis compounds cross the placenta and may interfere with cannabinoid receptors involved in fetal brain development. These findings support caution around cannabis use during pregnancy, though observational data cannot confirm causation.
#14 Maternal Cannabis Use in Pregnancy and Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder in Offspring.
Citation: Andrade Chittaranjan. Maternal Cannabis Use in Pregnancy and Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder in Offspring.. The Journal of clinical psychiatry. 2024. PMID: 39724097.
Design: 6 Journal: 0 N: 2 Recency: 1 Pop: 3 Human: 1 Risk: -2
Maternal cannabis use during pregnancy affects up to 10% of pregnant women, yet its neurodevelopmental effects remain incompletely characterized; this meta-analysis of 13 observational studies provides quantified risk estimates (RR 1.30 for ASD) that clinicians need for evidence-based counseling and prenatal guidance. Given cannabinoids’ known capacity to cross the placental barrier and interact with fetal cannabinoid receptors critical for brain development, establishing even modest associations between gestational exposure and neurodevelopmental disorders has important implications for obstetric risk stratification and pregnancy management. These findings directly inform clinical decision-making regarding substance use screening, patient education, and the growing clinical need to
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Retrospective design — selection and information bias risk
Abstract: Up to 10% of women may use cannabis during pregnancy; this is of concern because constituents of cannabis cross the placental barrier and potentially influence neurodevelopment by acting on cannabinoid receptors in the developing fetal brain. In this context, a recent meta analysis of 13 observational studies found that gestational exposure to cannabis was associated with a small increase in the risk of autism spectrum disorder (ASD; relative risk [RR], 1.30) and with an even smaller increase in the risk of attention deficit/hyperactivity disorder (ADHD; RR, 1.13); the latter finding was probably supported by publication bias. In this meta-analysis, 4 studies provided information on ASD (pooled N = 178,565) and 10 on ADHD (pooled N = 203,783). In a large (n = 222,534) retrospectively ascertained cohort study published after the meta-analysis, cannabis use disorder (CUD) recorded before pregnancy, during pregnancy, and during pregnancy plus the year after delivery were associated with closely similar increased risks of ASD (RRs, 3.02-3.21). The risks were smaller in smokers (RRs, 1.74-1.87) than in nonsmokers (RRs, 4.55-4.83) but differed little between male (RRs, 3.01-3.06) and female (RRs, 2.71-2.85) offspring. Although the cohort study had many strengths, its limitations permitted only the conclusion that peri-pregnancy exposure to CUD is associated with a large increase in the risk of ASD in offspring; it remained possible that much of the risk was driven by genetic, environmental, or behavioral variables. The field is nascent; the total number of cannabis exposed pregnancies (with ASD and ADHD as the outcomes) in world literature is small. However, cannabis use during pregnancy is, at the very least, a clear marker for adverse neurodevelopmental outcomes, besides the adverse maternal, fetal, and neonatal outcomes identified in other studies. Healthcare providers who manage women who use cannabis during pregnancy need to be aware of these adverse outcomes.
🧠 While this meta-analysis suggests a modest association between prenatal cannabis exposure and autism spectrum disorder risk, clinicians should recognize that the included studies were predominantly observational and subject to significant confounding, including unmeasured maternal psychiatric conditions, concurrent substance use, socioeconomic factors, and potential selection bias in reporting cannabis use. The absolute risk increase appears small, and heterogeneity across studies raises questions about the robustness of the pooled estimate, particularly given that some included cohorts may have had incomplete neurodevelopmental follow-up or diagnostic ascertainment variability. From a practical standpoint, this evidence supports counseling pregnant patients and those planning pregnancy to minimize or eliminate cannabis use when possible, while recognizing that the existing data cannot definitively establish causation and should be contextualized within the broader discussion of modifiable risk factors for neurodevelopmental disorders during pregnancy.